Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Silence Therapeutics doses first patient in ATU-027 trial for solid tumors

June 26, 2009

Cytopia files IND with FDA for JAK2 inhibitor CYT-387

June 26, 2009

ActoGeniX receives FDA approval to initiate phase Ib clinical trials of AG-013 in cancer

June 26, 2009

Provectus initiates compassionate-use program in Australia for PV-10 in cancer

June 25, 2009

Enzon initiates phase II trial of cancer drug PEG-SN38 in metastatic colon cancer

June 25, 2009

Prospect Therapeutics to develop GCS-100 for blood-borne cancers

June 25, 2009

Takeda presents novel MEK/ERK inhibitors as oncolytics

June 25, 2009

Sarcoma treatment snapshots from ASCO

June 25, 2009

Vical receives milestone payment from Merck & Co. for pDNA cancer vaccine

June 23, 2009

GlaxoSmithKline launches Tykerb for HER2-positive breast cancer in Japan

June 23, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...